Medicare often makes National Coverage Determinations which set forth the extent to which Medicare will cover specific services, procedures, or technologies on a national basis.  Medicare has begun  making such a determination for MAT®Treatment (Metabolic Activation Therapy),  under the broader class of therapies it terms “outpatient intravenous insulin  therapy”.  

The Coverage Determination process starts with a National Coverage Analysis.  TheTracking Sheet describes the National Coverage Analysis for this therapy – NCA for Outpatient Intravenous Insulin Treatment (CAG-00410N).    The National Coverage Analysis process also included Public Comments.  Dr. Aoki and others from ADRI posted comments.

Copyright ©2015 Aoki Diabetes Research Institute. ALL RIGHTS RESERVED